[go: up one dir, main page]

MX9707669A - Uso del factor neurotrofico glial (gdnf) para el tratamiento de padecimientos del oido. - Google Patents

Uso del factor neurotrofico glial (gdnf) para el tratamiento de padecimientos del oido.

Info

Publication number
MX9707669A
MX9707669A MX9707669A MX9707669A MX9707669A MX 9707669 A MX9707669 A MX 9707669A MX 9707669 A MX9707669 A MX 9707669A MX 9707669 A MX9707669 A MX 9707669A MX 9707669 A MX9707669 A MX 9707669A
Authority
MX
Mexico
Prior art keywords
gdnf
neurotrophic factor
treatment
hearing disorders
glial neurotrophic
Prior art date
Application number
MX9707669A
Other languages
English (en)
Inventor
Ella Magal
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/606,176 external-priority patent/US5837681A/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX9707669A publication Critical patent/MX9707669A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion se relaciona de manera general con los métodos para prevenir y/o tratar el daño o degeneracion de las células ciliadas cocleares (y vestibulares) y las neuronas del ganglio espiral administrando factor neurotrofico derivado del linaje celular glial (GDNF). La invencion se relaciona de manera más específica con los métodos para tratar la pérdida del oído sensorineural.
MX9707669A 1996-02-23 1997-02-14 Uso del factor neurotrofico glial (gdnf) para el tratamiento de padecimientos del oido. MX9707669A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/606,176 US5837681A (en) 1996-02-23 1996-02-23 Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US08/710,219 US5929041A (en) 1996-02-23 1996-09-13 Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
PCT/US1997/002677 WO1997030722A1 (en) 1996-02-23 1997-02-14 Use of glial neurotrophic factor (gdnf) for treatment of hearing disorders

Publications (1)

Publication Number Publication Date
MX9707669A true MX9707669A (es) 1997-11-29

Family

ID=27085161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707669A MX9707669A (es) 1996-02-23 1997-02-14 Uso del factor neurotrofico glial (gdnf) para el tratamiento de padecimientos del oido.

Country Status (21)

Country Link
US (1) US5929041A (es)
EP (1) EP0822829B1 (es)
JP (1) JP4028598B2 (es)
KR (1) KR100271247B1 (es)
CN (1) CN1130221C (es)
AT (1) ATE211392T1 (es)
AU (1) AU691443B2 (es)
CA (1) CA2217565C (es)
CZ (1) CZ322797A3 (es)
DE (1) DE69709458T2 (es)
DK (1) DK0822829T3 (es)
EA (1) EA199700225A1 (es)
ES (1) ES2170938T3 (es)
HU (1) HU223999B1 (es)
IL (1) IL121790A (es)
MX (1) MX9707669A (es)
NO (1) NO974767L (es)
NZ (1) NZ328918A (es)
PT (1) PT822829E (es)
SK (1) SK138697A3 (es)
WO (1) WO1997030722A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues
SI1005358T1 (en) * 1997-07-30 2003-06-30 Amgen Inc. Use of a neurturin protein product for preventing and treating hearing loss
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US7236888B2 (en) * 1998-03-06 2007-06-26 The Regents Of The University Of California Method to measure the activation state of signaling pathways in cells
US6309410B1 (en) 1998-08-26 2001-10-30 Advanced Bionics Corporation Cochlear electrode with drug delivery channel and method of making same
US6304787B1 (en) 1998-08-26 2001-10-16 Advanced Bionics Corporation Cochlear electrode array having current-focusing and tissue-treating features
ES2288042T3 (es) 1998-09-25 2007-12-16 Cephalon, Inc. Uso de pirrolocarbazoles condensados para prevenir/tratar daños de las celulas ciliadas sensoriales y neuronas cocleares.
JP2003530817A (ja) * 1999-06-01 2003-10-21 ベイラー カレッジ オブ メディスン 聴覚障害、変形性関節症および細胞の異常増殖に関するａｔｏｎａｌ関連配列の治療用途のための組成物および方法
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
EP1223966B1 (en) * 1999-10-29 2003-05-02 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Use of gdnf for treating corneal defects
US6551575B1 (en) 1999-12-02 2003-04-22 Neurosciences Research Foundation, Inc. Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity
DE10025152A1 (de) * 2000-05-23 2001-12-06 Marlies Knipper Neurotrophin stimulierende Substanzen, insbesondere Thyroidhormon (T3) oder Schilddrüsenhormon stimulierende Substanzen, für die therapeutische Behandlung von lärm-und altersbedingter Schwerhörigkeit
AUPR148400A0 (en) * 2000-11-14 2000-12-07 Cochlear Limited Apparatus for delivery of pharmaceuticals to the cochlea
US9089450B2 (en) * 2000-11-14 2015-07-28 Cochlear Limited Implantatable component having an accessible lumen and a drug release capsule for introduction into same
US20030191064A1 (en) * 2001-01-23 2003-10-09 Kopke Richard D. Methods for preventing and treating loss of balance function due to oxidative stress
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
AUPS081502A0 (en) * 2002-02-28 2002-03-21 Cochlear Limited Connector for drug delivery system
JP4533144B2 (ja) * 2002-10-02 2010-09-01 アンジェスＭｇ株式会社 聴覚機能障害用医薬
US8515560B2 (en) * 2002-11-29 2013-08-20 Cochlear Limited Medical implant drug delivery device
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US8133215B2 (en) * 2007-08-13 2012-03-13 Cochlear Limited Independently-manufactured drug delivery module and corresponding receptacle in an implantable medical device
WO2009029866A2 (en) * 2007-08-29 2009-03-05 Advanced Bionics, Llc Minimizing trauma during and after insertion of a cochlear lead
US8271101B2 (en) * 2007-08-29 2012-09-18 Advanced Bionics Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR102340754B1 (ko) 2008-04-21 2021-12-16 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US8617097B2 (en) 2010-05-24 2013-12-31 Cochlear Limited Drug-delivery accessory for an implantable medical device
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
EP2968462B1 (en) 2013-03-15 2020-12-23 The Jackson Laboratory Methods for promoting wound healing and hair growth
EP3113788A4 (en) 2014-03-05 2017-10-18 Lawrence M. Schwartz Methods and compositions for the protection of sensory cells
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
CN109414501A (zh) * 2016-05-03 2019-03-01 斯克利普斯研究院 用于治疗神经退行性疾病的TrkB激动剂抗体
NZ754163A (en) 2016-11-10 2026-01-30 Keros Therapeutics Inc Gdnf fusion polypeptides and methods of use thereof
EP3406259A1 (en) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
SI3737233T1 (sl) * 2018-01-09 2025-10-30 Dompé Farmaceutici S.P.A. Ušesne formulacije z rastnimi faktorji
CN112920998B (zh) * 2021-02-05 2022-06-14 复旦大学附属眼耳鼻喉科医院 一种成年鼠耳蜗体培养体系的建立方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
EP0610254B1 (en) * 1991-09-20 2004-09-01 Amgen Inc. Glial derived neurotrophic factor
ES2178654T3 (es) * 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods

Also Published As

Publication number Publication date
CN1181704A (zh) 1998-05-13
IL121790A0 (en) 1998-02-22
CA2217565C (en) 2002-04-16
DE69709458T2 (de) 2002-08-29
JP4028598B2 (ja) 2007-12-26
PT822829E (pt) 2002-06-28
NO974767L (no) 1997-12-22
US5929041A (en) 1999-07-27
EP0822829A1 (en) 1998-02-11
NZ328918A (en) 1999-08-30
KR19980703748A (ko) 1998-12-05
NO974767D0 (no) 1997-10-15
KR100271247B1 (ko) 2000-11-01
JPH11504351A (ja) 1999-04-20
EA199700225A1 (ru) 1998-04-30
HUP9901758A3 (en) 2001-10-29
EP0822829B1 (en) 2002-01-02
CA2217565A1 (en) 1997-08-28
DE69709458D1 (de) 2002-02-07
HUP9901758A2 (hu) 1999-08-30
WO1997030722A1 (en) 1997-08-28
IL121790A (en) 2002-08-14
ATE211392T1 (de) 2002-01-15
ES2170938T3 (es) 2002-08-16
SK138697A3 (en) 1998-02-04
AU2277997A (en) 1997-09-10
AU691443B2 (en) 1998-05-14
CN1130221C (zh) 2003-12-10
DK0822829T3 (da) 2002-04-02
HU223999B1 (hu) 2005-04-28
CZ322797A3 (cs) 1998-01-14

Similar Documents

Publication Publication Date Title
MX9707669A (es) Uso del factor neurotrofico glial (gdnf) para el tratamiento de padecimientos del oido.
DK1005358T3 (da) Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse
DK0866719T3 (da) Fremgangsmåde til behandling af retina-gangliecellelæsion under anvendelse af gliacellelinjeafladt neurotrof faktor (GDNF)-
AU2003296958A1 (en) Therapeutic retroviral vectors for gene therapy
PT923293E (pt) Tratamento da diarreia
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
EP0958831A4 (en) OPHTHALMIC COMPOSITIONS OF NEUROTROPHIC FACTORS, REMEDIES FOR FUNCTIONAL OPTIC NERVE DISORDERS AND METHOD FOR TREATING SUCH DISORDERS
ES2074276T3 (es) Metodo de tratamiento de la alopecia.
ATE319712T1 (de) Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
AU2838101A (en) Use of melatonin for treating androgenetic and diffuse alopecia
CA2347863A1 (en) Treatment of disorders of the outer retina
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
CA2249666A1 (en) Macrophage stimulating protein for the treatment of gastrointestinal disorders
DE3866757D1 (de) Prothese und elektrode zur elektrischen stimulation des innenohres und verfahren zur herstellung dieser elektrode.
Hamdan-Allen Brief report: trichotillomania in an autistic male.
WO2002004605A3 (en) Stimulation of cellular regeneration and differentiation in the inner ear
DE60039579D1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
Rahko et al. Tinnitus treatment by transcutaneous nerve stimulation (TNS)
EP1304119A3 (en) Method for preventing and treating hearing loss using a neurturin protein product
ATE296636T1 (de) Verbesserter heilungsprozess von neuralverletzungen anhand von cm101/gbs-toxin
WO2001072955A3 (en) Regulation of human nedd1-related protein
WO2024173581A3 (en) Formulations for the treatment of skin diseases and conditions
MD404C2 (ro) Stimulator aeroionic de modulare
WO2000021978A3 (en) Laminin 5, 13 and 14 and uses thereof
UA29648A (uk) Спосіб лікування хімічних опіків стравоходу